Delisting risk
Regentis Biomaterials (RGNT)
Develops a cell-free hydrogel implant for focal knee-cartilage repair.
$2.00
Pre-market−0.02 (−0.96%)
At close$2.02(−1.94%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Insiders1 holder · as of Feb 17, 2026 | 18.98% | 1.33M shares | |
| Otherremainder | 81.02% | 5.69M shares |
7.02M company shares as of Aug 21, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Institutions13F
No 13F holders on record.
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Dr. Ehud Geller | 23.20% | 1.33M | 13G | Feb 17, 2026 ↗ |
Insider tradesForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.